TOP STORIES
respiratory
Bronchiectasis

Brensocatib reduces exacerbations in bronchiectasis: WILLOW study


A novel anti-inflammatory treatment for bronchiectasis that targets neutrophils has shown promising results in a phase 2 trial. In findings presented at ATS 2020 virtual meeting, brensocatib, a reversible inhibitor of dipeptidyl peptidase-1 (DPP1 inhibitor) showed positive effects against bronchietasis...

A novel anti-inflammatory treatment for bronchiectasis that targets neutrophils has shown promising results in a phase 2 trial. In findings presented...

Read more